Typewriter Therapeutics Emerges From Stealth With $56 Million Series A to Advance TPRT Non-Viral Gene Therapy Platform for In-Vivo CAR-T and Genetic Liver Diseases
Typewriter Therapeutics announced Thursday September 3, 2026 its emergence from stealth with $56 million in Series A financing co-led by RA Capital Management and AN Venture Partners, with participation from ANRI, Gemseki, and SBI US Gateway Fund. The proceeds will advance the company's target-primed reverse transcription (TPRT) non-viral gene therapy platform toward clinical development, with initial focus on two high-value indications: in-vivo CAR-T and genetic liver diseases. TPRT uses jumping-gene-inspired biology to insert therapeutic DNA at specific target sites without the packaging-size constraints of AAV vectors or the payload delivery constraints of lipid nanoparticles. Typewriter plans to initiate non-human primate studies in late 2026 and establish its first in-vivo CAR-T development candidate over the next 12 months. The financing continues the H2 2026 in-vivo CAR-T financing wave that also delivered Umoja Biopharma's $100 million+ round and Capstan Therapeutics' Series C earlier in the summer.